Transform: Teaching, Technology, and Teams
Status unconfirmed · Not applicable
Conditions studied: Heart Failure, Type 2 Diabetes, Atrial Fibrillation
In brief
This initiative supports a quality improvement effort evaluating the use of strategies (including technology-based decision support, referral to a virtual GDMT team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular (CV) events among patients with cardiovascular diseases of heart failure, atrial fibrillation and type 2 diabetes (T2D)/ASCVD with a specific focus on underserved populations and those with a history of health care disparities.
Key facts
- Study ID
- NCT05572814
- Run by
- American College of Cardiology
- People needed
- 750
- Starts
- 2022-09-30
- Expected to finish
- 2023-12-31
- Last updated by the study team
- 2022-10-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age ≥18 years
- Personal access to a computer and/or Smartphone for app download
- Heart Failure (reduced and preserved ejection fraction) AND/OR
- Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR
- T2D and ASCVD, defined as follows:
- Known CAD, prior ACS, or coronary artery revascularization
- Prior TIA/stroke or known carotid or intracerebral atherosclerosis
- Prior PAD including requiring revascularization
You may not qualify if…
- All patients
- Current or anticipated participation in an interventional clinical trial of a drug/device
- Currently receiving comfort care or enrolled in hospice
- Life expectancy <1 year
- Pregnancy or active breastfeeding
- Current or anticipated participation in an interventional clinical trial (other than TRANSFORM3 GDMT)
- Patients without a clinical encounter within three years of study start date
- Heart Failure patients:
- History of or plan for heart transplantation or left ventricular assist de-vice
- Palliative chronic inotropic therapy
- NYHA Class 4 heart failure
- Atrial Fibrillation patients:
- Current prescription for OAC
- Reversible cause of atrial fibrillation, such as post-cardiothoracic surgery or thyrotoxicosis
- History of ischemic stroke in prior 7 days
- Transient ischemic attack in prior 3 days
- Platelet count <70,000/ml
- Hemoglobin concentration <8g/dl
- History of or condition associated with increased bleeding risk, such as hemophilia
- Major surgical procedure or trauma within 14 days
- Clinically significant gastrointestinal bleeding within 8 weeks
Where it is running
- Cardiology Center of Amarillo — Amarillo, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.